CervoMed (CRVO) director receives options for 8,150 shares at $2.91 strike

Rhea-AI Filing Summary

CervoMed Inc. director Jane H. Hollingsworth received a stock option grant tied to her election to the board. The award covers 8,150 shares of CervoMed common stock with an exercise price of $2.91 per share and expires on June 8, 2036.

The option was granted under CervoMed’s 2025 Equity Incentive Plan in line with its non-employee director compensation policy. The underlying shares vest monthly over one year in substantially equal 1/12th increments on the last day of each month beginning on June 30, 2026, contingent on continued board service.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider Hollingsworth Jane H

Role null

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (Right to Buy)	8,150	$0.00	--

Holdings After Transaction: Stock Option (Right to Buy) — 8,150 shares (Direct, null)

Footnotes (1)

1. [object Object]

Key Figures

Option grant size: 8,150 shares Exercise price: $2.91 per share Expiration date: June 8, 2036 +2 more

5 metrics

Option grant size 8,150 shares Underlying common stock in director option award

Exercise price $2.91 per share Strike price for CervoMed stock options

Expiration date June 8, 2036 Option term end date for director grant

Vesting schedule 1/12 monthly over 1 year Vests last day of each month starting June 30, 2026

Shares owned after transaction 8,150 derivative shares Total stock options held following this grant

Key Terms

Stock Option (Right to Buy), 2025 Equity Incentive Plan, non-employee director compensation policy, vest on a monthly basis, +1 more

5 terms

Stock Option (Right to Buy) financial

"security_title: "Stock Option (Right to Buy)""

2025 Equity Incentive Plan financial

"granted an option ... under the Issuer's 2025 Equity Incentive Plan"

non-employee director compensation policy financial

"in accordance with the terms of the Issuer's non-employee director compensation policy"

vest on a monthly basis financial

"shares of common stock underlying the award will vest on a monthly basis"

beneficial ownership financial

"subject to the Reporting Person's continued service through the applicable vesting date."

Beneficial ownership means the person or entity that actually enjoys the benefits of owning shares or other assets — such as receiving dividends, voting rights, or price gains — even if the legal title is held in another name. For investors it matters because knowing who truly controls and profits from a company reveals who can influence decisions, exposes potential conflicts of interest or hidden concentration of power, and affects transparency and risk in the stock.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Hollingsworth Jane H

(Last) (First) (Middle)

20 PARK PLAZA, SUITE 424

(Street)

BOSTON MASSACHUSETTS 02116

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
CervoMed Inc. [ CRVO ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/08/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$2.91	06/08/2026		A		8,150		(1)	06/08/2036	Common Stock	8,150	$0	8,150	D

Explanation of Responses:

1. On June 8, 2026, in connection with the Reporting Person's election to the Issuer's board of directors at its 2026 Annual Meeting of Stockholders, the Reporting Person was granted an option to purchase 8,150 shares of the Issuer's common stock under the Issuer's 2025 Equity Incentive Plan in accordance with the terms of the Issuer's non-employee director compensation policy. The shares of common stock underlying the award will vest on a monthly basis over a one-year period in substantially equal 1/12th increments on the last day of each month beginning on June 30, 2026, subject to the Reporting Person's continued service through the applicable vesting date.

	/s/ William R. Elder, attorney-in-fact for the Reporting Person	06/10/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What insider transaction did CervoMed (CRVO) disclose for Jane H. Hollingsworth?

CervoMed disclosed that director Jane H. Hollingsworth received a stock option grant for 8,150 shares. The options were awarded in connection with her election to the board under the company’s 2025 Equity Incentive Plan and follow its non-employee director compensation policy.

What are the key terms of Jane Hollingsworth’s CervoMed (CRVO) stock option grant?

The stock option grant covers 8,150 underlying common shares at an exercise price of $2.91 per share. The options expire on June 8, 2036 and were issued under CervoMed’s 2025 Equity Incentive Plan as part of non-employee director compensation.

How do Jane Hollingsworth’s CervoMed (CRVO) options vest?

The 8,150-share option award vests monthly over one year in substantially equal 1/12th installments. Vesting occurs on the last day of each month starting on June 30, 2026, and depends on her continued service on CervoMed’s board through each vesting date.

Did Jane Hollingsworth buy or sell CervoMed (CRVO) shares in this Form 4?

This Form 4 reports a grant of stock options, not an open-market buy or sale. Jane Hollingsworth acquired derivative rights to purchase 8,150 CervoMed shares as director compensation, with no reported market transaction in the company’s common stock in this filing.

What is the expiration date of Jane Hollingsworth’s CervoMed (CRVO) option award?

Jane Hollingsworth’s stock options expire on June 8, 2036, giving her roughly ten years from grant to exercise them. The options must be vested before exercise and remain subject to the terms of CervoMed’s 2025 Equity Incentive Plan and applicable agreements.